Soleno Therapeutics, Inc.
Soleno Therapeutics, Inc.（SLNO）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · SLNO · 截至 2026年6月8日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
7
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Soleno Therapeutics, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
SLNO 季度内部人买卖趋势
SLNO 内幕交易卖出 · SLNO 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · SLNO CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
SLNO 高管卖出股份 · SLNO 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| May 18, 2026 | Yen Kristen SEE REMARKS | Other | 37,639 | — | Form 4 |
| May 18, 2026 | Volck Birgitte Director | Other | 17,536 | — | Form 4 |
| May 18, 2026 | Sinclair Andrew Director | Other | 10,491 | — | Form 4 |
| May 18, 2026 | Pauls Matthew Director | Other | 10,491 | — | Form 4 |
| May 18, 2026 | Norrett Kevin Chief Business Officer | Other | 17,786 | — | Form 4 |
| May 18, 2026 | Manning Meredith Chief Commercial Officer | Other | 64,507 | — | Form 4 |
| May 18, 2026 | Joshi Manher Chief Development Officer | Other | 20,171 | — | Form 4 |
| May 18, 2026 | Huang Michael F. Sr. VP of Clinical Development | Other | 39,823 | — | Form 4 |
| May 18, 2026 | Hirano Patricia C SEE REMARKS | Other | 22,702 | — | Form 4 |
| May 18, 2026 | Hahn Mark W Director | Other | 10,046 | — | Form 4 |
| May 18, 2026 | Fulk Jennifer CHIEF FINANCIAL OFFICER | Other | 39,200 | — | Form 4 |
| May 18, 2026 | Bir Dawn Carter Director | Other | 16,991 | — | Form 4 |
| May 18, 2026 | Anish Bhatnagar CHIEF EXECUTIVE OFFICER · Director | Other | 583,656 | — | Form 4 |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 4,864 | $146K | Form 4 |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 2,100 | $65K | Form 4 |
| Mar 27, 2026 | Manning Meredith Chief Commercial Officer | Sale | 558 | $18K | Form 4 |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 4,256 | $128K | Form 4 |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 1,838 | $57K | Form 4 |
| Mar 27, 2026 | Huang Michael F. Sr. VP of Clinical Development | Sale | 488 | $15K | Form 4 |
| Mar 2, 2026 | Fulk Jennifer CHIEF FINANCIAL OFFICER | Award | 39,200 | — | Form 4 |
| Jan 21, 2026 | Yen Kristen SEE REMARKS | Award | 10,400 | — | Form 4 |
| Jan 21, 2026 | Norrett Kevin Chief Business Officer | Award | 3,500 | — | Form 4 |
| Jan 21, 2026 | Manning Meredith Chief Commercial Officer | Award | 28,600 | — | Form 4 |
| Jan 21, 2026 | Mackaness James H CHIEF FINANCIAL OFFICER | Award | 28,600 | — | Form 4 |
| Jan 21, 2026 | Joshi Manher Chief Development Officer | Award | 4,100 | — | Form 4 |
Anish Bhatnagar
CHIEF EXECUTIVE OFFICER · Director
日期
May 18
股数
583,656
均价
—
总金额
—
Huang Michael F.
Sr. VP of Clinical Development
日期
Mar 27
股数
4,256
均价
$30.04
总金额
$128K
Huang Michael F.
Sr. VP of Clinical Development
日期
Mar 27
股数
1,838
均价
$31.04
总金额
$57K
Huang Michael F.
Sr. VP of Clinical Development
日期
Mar 27
股数
488
均价
$31.72
总金额
$15K
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 SLNO 内幕交易
SLNO 内幕交易
Soleno Therapeutics, Inc.（SLNO）内幕交易数据来源于公司内部人（包括Manning Meredith (Chief Commercial Officer), Huang Michael F. (Sr. VP of Clinical Development), Yen Kristen (SEE REMARKS)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。SLNO内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Soleno Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
SLNO 内幕交易 · 5个问题Soleno Therapeutics, Inc.（SLNO）的内部人包括高管和董事，如Manning Meredith (Chief Commercial Officer), Huang Michael F. (Sr. VP of Clinical Development), Yen Kristen (SEE REMARKS)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026